3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Dermatologic
2
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
3
Urinary Bladder Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Cancer
1
Interventions
Sunitinib
86
Sorafenib
60
Everolimus
47
pazopanib
46
Bevacizumab
46
Nivolumab
44
pembrolizumab
37
aldesleukin
29
Interferon-alpha
26
Axitinib
24
temsirolimus
23
cabozantinib
20
Interleukin-2
19
Ipilimumab
16
Interferon alpha-2
15
Cyclophosphamide
15
fludarabine phosphate
14
Gemcitabine
14
Peripheral Blood Stem Cell Transplantation
11
Sirolimus
10
Paclitaxel
10
Erlotinib Hydrochloride
10
avelumab
8
Radiosurgery
8
Docetaxel
8
Cyclosporine
8
Capecitabine
8
tremelimumab
7
lenvatinib
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Renal Cell
×
bempegaldesleukin
×
Clear all
NCT03548467
2023-04-21
DIRECT-01
Nykode Therapeutics ASA
Phase 1/2
Completed
41 enrolled
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts